293306-94-2Relevant academic research and scientific papers
Radical cascade synthesis of azoles: via tandem hydrogen atom transfer
Chen, Andrew D.,Herbort, James H.,Mustafa, Darsheed N.,Nagib, David A.,Nakafuku, Kohki M.,Wappes, Ethan A.
, p. 2479 - 2486 (2020/03/19)
A radical cascade strategy for the modular synthesis of five-membered heteroarenes (e.g. oxazoles, imidazoles) from feedstock reagents (e.g. alcohols, amines, nitriles) has been developed. This double C-H oxidation is enabled by in situ generated imidate
A novel synthetic method of 2,4-disubstituted oxazoles using carboxylic acid-derived Bu2Sn[OC(O)R]2
Yoneyama, Hiroki,Oka, Naoki,Usami, Yoshihide,Harusawa, Shinya
supporting information, (2020/05/21)
A novel synthetic method for the preparation of 2,4-disubstituted oxazoles was developed, entailing the reaction of dibutyltin diacylates Bu2Sn[OC(O)R]2 with 1-substituted acetylenes and TMSN3 to afford a range of 2,4-disu
Divergent Palladium-Catalyzed Tandem Reaction of Cyanomethyl Benzoates with Arylboronic Acids: Synthesis of Oxazoles and Isocoumarins
Chen, Jiuxi,Chen, Zhongyan,Dai, Ling,Shao, Yinlin,Xiong, Wenzhang,Xu, Tong,Yu, Shuling
supporting information, (2020/04/15)
A palladium-catalyzed tandem reaction of cyanomethyl benzoates with arylboronic acids has been achieved. Substitution at the 2-position of cyanomethyl benzoates was found to be crucial for the selective synthesis of oxazoles and isocoumarins. Cyanomethyl
Substituted oxazole benzenesulfonamides as potent human β3 adrenergic receptor agonists
Ok,Reigle,Candelore,Cascieri,Colwell,Deng,Feeney,Forrest,Hom,MacIntyre,Strader,Tota,Wang,Wyvratt,Fisher,Weber
, p. 1531 - 1534 (2007/10/03)
As a part of our investigation into the development of orally bioavailable β3 adrenergic receptor agonists, we have identified a series of substituted oxazole derivatives that are potent β3 agonists with excellent selectivity against other β receptors. Several of these compounds showed excellent oral bioavailability in dogs. One example, cyclopentylethyloxazole 5f is a potent β3 agonist (EC50 = 14 nM, 84% activation) with 340-fold and 160-fold selectivity over β1 and β2 receptors, respectively, and has 38% oral bioavailability in dogs. (C) 2000 Elsevier Science Ltd. All rights reserved.
